Search

Displaying results 9221 - 9230 of 9431 in total
  1. Drug

    ENMD-1198

    go.drugbank.com/drugs/DB05959
    Experimental

  2. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magneti...

  3. Drug

    Girentuximab

    go.drugbank.com/drugs/DB05304
    Investigational

    Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).

  4. Drug

    SL017

    go.drugbank.com/drugs/DB05156
    Experimental

    SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis

  5. Drug

    Tagetitoxin

    go.drugbank.com/drugs/DB04788
    Experimental

    Tagetitoxin is a bacterial phytotoxin. It preferentially inhibits eukaryotic RNA polymerase.

  6. Drug

    Adenine

    go.drugbank.com/drugs/DB00173
    ApprovedInvestigationalNutraceutical

    A purine base and a fundamental unit of adenine nucleotides.

  7. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  8. Drug

    Tin protoporphyrin IX

    go.drugbank.com/drugs/DB16449
    Investigational

  9. Drug

    Collagen-polyvinylpyrrolidone

    go.drugbank.com/drugs/DB16525
    Investigational

    Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation . It is characterized by antifibrotic, fibrolytic, and immunomodulatory properties .

  10. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.